Disclosures for "Novel Risk Factors for Predicting Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS)"
-
Dr. Friedman has nothing to disclose.
-
Ceren Tozlu has nothing to disclose.
-
Mr. Gordillo has nothing to disclose.
-
Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Allogene. Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gilead. Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Incyte. Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Instil Bio. Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TScan. Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Synthekine. Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orca. Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Quell. Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Capstan. Ran Reshef has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jasper. Ran Reshef has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Bayer. The institution of Ran Reshef has received research support from Atara. The institution of Ran Reshef has received research support from Incyte. The institution of Ran Reshef has received research support from Sanofi. The institution of Ran Reshef has received research support from Immatics. The institution of Ran Reshef has received research support from Abbvie. The institution of Ran Reshef has received research support from TCR2. The institution of Ran Reshef has received research support from Takeda. The institution of Ran Reshef has received research support from Gilead. The institution of Ran Reshef has received research support from CareDx. The institution of Ran Reshef has received research support from TScan. The institution of Ran Reshef has received research support from Synthekine. The institution of Ran Reshef has received research support from BMS. The institution of Ran Reshef has received research support from Janssen. The institution of Ran Reshef has received research support from Genentech. The institution of Ran Reshef has received research support from Precision.
-
Dr. Wesley has nothing to disclose.